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Abstract
Background: Single-tablet regimens are preferred prescription choices for HIV treatment, but there are limited outcomes
data comparing single-tablet regimens to multiple-tablet regimens.
Methods: We retrospectively assessed treatment-naïve patients at a single urban HIV clinic in the United States for viral
load suppression at 6 and 12 months after initiating either single-tablet or multiple-tablet regimens. Multivariate regression
was performed to obtain relative risks and adjust for potential confounders.
Results: Of 218 patients, 47% were on single-tablet regimens and 53% on multiple-tablet regimens; 77% of single-tablet
regimen patients had undetectable viral load at 6 months compared to 61% of multiple-tablet regimen patients (p = 0.012).
At 12 months, 82% on single-tablet regimens and 66% on multiple-tablet regimens (p = 0.019) had undetectable viral load.
Relative risk of any detectable viral load was 1.6 (95% confidence interval: 1.1–2.5) for patients on multiple-tablet regimens
compared to single-tablet regimens at 6 months, and 2.2 (95% confidence interval: 1.2–4.0) at 12 months.
Conclusion: Single-tablet regimens may provide better virologic control than multiple-tablet regimens in urban HIV-infected
persons.
Keywords
HIV, antiretroviral therapy, sexually transmitted infections, fixed-dosed combinations, single-tablet regimens
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Background
Since the advent of antiretroviral (ARV) therapy for human
immunodeficiency virus (HIV), treatment regimens have
changed from complex, burdensome regimens to one pill
once daily. Fixed-dose combination (FDC) pills for HIV are
readily available and frequently used. Of the recommended
initial regimens in the US Department of Health and Human
Services’ (DHHS) treatment guidelines from October 2018,
five are available as single-tablet regimens (STR).1
The importance of adherence to ARV therapy has been
well-described, with poor adherence being associated with
virologic failure and subsequent disease progression.2–6
Multiple studies have shown that adherence to ARV therapy is
improved by switching to a regimen with lower pill burden.7–12
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A meta-analysis by Nachega et al.13 of twice-daily versus
once-daily dosing across all regimens showed an improvement of both adherence and virologic suppression with
decrease in pill burden, but this was modest at best, and most
commonly seen in treatment-naïve patients. While the above
studies have investigated the effects of once-daily dosing and
pill burden, none have directly assessed the use of STR.
Several observational studies have evaluated the effect of
STR on factors such as adherence, patient satisfaction, hospitalization risks, and costs with mixed results.9,14–19 Both Sax
et al.18 and Cohen et al.16 showed improvement in hospitalization rates among patients using STR compared to multipletablet regimens (MTR). Bangsberg et al.14 showed
improvements in both adherence and virologic suppression in a
population of marginally housed and homeless persons in San
Francisco. Altogether, however, relatively few studies have
assessed the impact of STR specifically compared to MTR for
the outcome of virologic failure in a clinic population.
Understanding the impact of STR is especially important
today, as we stand on the verge of multiple effective agents
being available as generic formulations with the potential to
decrease the cost of ARV therapy, and affect significant costsavings nationally, as shown by Walensky et al.20 in 2013.
These cost-savings may result in a “desimplification” of
treatment as patients on currently branded STR may be asked
to change to a less costly multiple-pill alternative. The
impact of such a proposed switch toward higher pill burden
on adherence and outcome, especially in vulnerable populations, needs to be assessed.
We assessed virologic suppression at 6 and 12 months
among urban ARV therapy-naïve patients starting their first
regimen and compared virologic and immunologic outcomes
of patients on STR with those on MTR.
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(PCR) (“viral load”), previously never on ARV therapy, had a
CD4+ T-lymphocyte count and HIV RNA viral load in their
medical record before initiation of ARV therapy (“baseline”),
and at least one additional CD4 count and viral load at least
6 months after initiation of ARV therapy. Furthermore, eligible
patients were subsequently started on STR or MTR as chosen
by their provider, and continued on an uninterrupted and
unchanged (as noted by the physician in the medical record)
ARV regimen for a minimum of 6 months; patients switching
therapy after 6 months were included in the study; however,
12-month data were censored.
Patient data were excluded if the patient did not complete
6 months of uninterrupted or unchanged ARV regimen. We
defined an “interrupted” ARV regimen as a physician directive to stop taking medication. Patients were also excluded if
baseline or 6-months post–ARV initiation CD4 count and
viral load laboratory values were not present in the medical
record.

ARV regimens
STR acceptable for inclusion consisted of the following
three FDC pills: (1) emtricitabine, rilpivirine, and tenofovir
disoproxil fumarate (TDF) (brand name Complera®); (2)
efavirenz, emtricitabine, and TDF (brand name Atripla®), or
(3) elvitegravir, cobicistat, emtricitabine, and TDF (brand
name Stribild®), taken as one tablet once daily.
MTR acceptable for inclusion consisted of a nucleoside/
nucleotide reverse transcriptase inhibitor, non-nucleoside/
nucleotide reverse transcriptase inhibitor, protease inhibitor
(PI), entry inhibitor, integrase inhibitor, or chemokine receptor 5 antagonist taken in any formulation of two or more tablets or capsules daily.

Methods

Data collection

Study design and setting

Two study staff reviewed the medical record of every HIVinfected patient newly presenting to the IDP between 2006 and
2013. Data collected were age, gender, ethnicity, specific ARV
medication regimen, date of ARV initiation, as well as baseline,
6 month, 12 month, and most recent (at time of data collection)
HIV viral load and CD4 count. The nearest value, in time, to
the 6- or 12-month point was recorded for each patient. Current
or past history of any treated or untreated mental illness, including depression, schizophrenia, bipolar disorder, and anxiety, as
evidenced by either a formally listed diagnosis with ICD-9
(International Classification of Diseases) coding or a mention
in the narrative of a physician’s note was recorded. These same
criteria were used to determine inclusion of current or past substance use in study data; substances included were cocaine,
heroin, methamphetamine, phencyclidine, MDMA, lysergic
acid diethylamide, marijuana, and excessive alcohol use.
Moderate or minimal alcohol use without dependence (as
determined at the discretion of study staff because of variable
phrasing in physicians’ notes) was excluded.

This is a retrospective cohort study. Patients were enrolled in
the Infectious Disease Practice (IDP) at the New Jersey
Medical School in Newark, NJ. Of the patients seen at this
practice from 2007–2013, 46% were enrolled in Medicaid,
25% self-pay or in hospital-based charity care, 22% in
Medicare, and 7% with commercial insurance.

Study participants
After institutional internal review board approval, electronic
medical records of new patients presenting for HIV care at the
Infectious Diseases Practice between 2006 and 2013 were
evaluated. Patients selected for study inclusion were ⩾18 years
at initial visit, diagnosed as HIV-1 seropositive with a positive
secondary laboratory conformation in the form of an EnzymeLinked Immunosorbent Assay (ELISA)/Western Blot, or an
HIV-1 Ribonucleic Acid (RNA) Polymerase Chain Reaction
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Table 1. Baseline characteristics of study population by treatment regimen.
Characteristic
Mean age, years (SD)
Female (%)
Race/ethnicity
# Black (%)
# Hispanic (%)
# Other (%)
History of substance abuse
History of mental illness
Median HIV-1 viral load, copies/
mL (IQR)
Median CD4 count, mm3 (IQR)

All patients
(n = 218)
43.58 (11.50)
77 (35.32%)

Single-tablet
regimens (n = 103)
42.11 (12.25)
26 (25.24%)

Multiple-tablet
regimens (n = 115)
44.90 (10.66)
51 (44.35%)

P-valuea
0.074
0.003
0.025

136 (62.39%)
45 (20.64%)
37 (16.97%)
102 (46.79%)
61 (27.98%)
42,705.50 (147,500)

56 (54.37%)
29 (28.16%)
18 (17.48%)
41 (39.81%)
25 (24.27%)
45,679.00 (120,232)

80 (69.57%)
16 (13.91%)
19 (16.52%)
51 (53.04%)
36 (31.30%)
35,900.00 (151,529)

0.051
0.248
0.714

233.50 (261)

281.00 (290)

226.00 (249)

0.069

SD, standard deviation; IQR, interquartile range.
aThe Wilcoxon rank-sum test or the t-test (for age) assessed group differences in continuous variable. The Pearson chi-square test assessed group differences in categorical variables.
Bold value represents an alpha of 0.05.

Outcomes

Results

Primary outcome was defined as HIV viral load below the
limit of quantification (“undetectable”) of the specific sensitivity of the PCR utilized in analyzing each unique blood
sample 6 months after initiation of first ARV regimen. For
the majority of patients seen prior to 2012, the lower limit
of quantification was <48 copies/mL. For the majority of
patients seen after 2012, the lower limit of quantification
was <20 copies/mL. Secondary outcomes were viral load
12 months after initiation of first ARV regimen, and CD4
counts 6 and 12 months after initiation.

Baseline characteristics

Data analysis
Statistical analyses were performed using SAS software
(SAS Institute, Cary, NC). Baseline characteristics were
considered at the medical visit at which ARV therapy was
started. The Wilcoxon rank-sum test or the t-test were
used to analyze differences in continuous variables.
Pearson chi-square analysis was used for categorical variables. Differences between treatment groups in primary
and secondary outcome measures at 6 and 12 months were
performed using Pearson chi-square tests for viral load
detectability (yes vs no) and the Wilcoxon rank-sum test
for median CD4 count and CD4 count change. Multivariate
log binomial regression analysis was performed to determine relative risks (RRs) for two models: (1) all patients,
controlling for age, gender, mental illness, substance use
disorder, and baseline viral load, and (2) for Black and
Hispanic patients only, controlling for age, gender, mental
illness, substance use disorder, baseline viral load, and
race/ethnicity. The second model was performed to allow
adjustment for race/ethnicity, which was not included in
the first model because of low numbers of other-race
patients.

A total of 218 patients met the inclusion criteria. Of these, 103
(47%) were initiated on STR and 115 (53%) on MTR. Table 1
shows the differences in the baseline characteristics between
the two groups. Patients in the STR group were less likely to
be female (25% vs 44%, p < 0.005) and less likely to be Black
(54% vs 70%, p = 0.025). A higher proportion of patients in the
MTR group had a reported history of substance abuse: 53%
compared to 39% in the STR group (p = 0.051).
Baseline virologic characteristics were similar between the
two groups. Median HIV viral load for each group was comparable. The MTR group had a lower median CD4 count of 226
cells/mm3 as compared to 281 cells/mm3 in the STR group, but
the difference was not statistically significant (p = 0.069).
Of the 103 patients on STR, 93 (91%) were on a FDC of
efavirenz, TDF, and emtricitabine. Three patients (3%) were
on a FDC of elvitegravir, cobicistat, TDF, and emtricitabine;
and 7 (6%) on a FDC of rilpivirine, TDF, and emtricitabine.
The MTR regimens were more diverse: All patients were
treated with a dual-nucleoside backbone. Forty-five patients
(39%) were on boosted atazanavir, 34 (29%) on boosted darunavir, 22 patients (19%) on raltegravir, 9 (8%) on boosted
fosamprenavir, 4 (3%) on boosted lopinavir, and 1 (<1%) on
neviripine. Of the nucleoside backbones, 105 (91%) were
TDF with emtricitabine, 7 (6%) were abacavir with lamivudine, and 3 (3%) were zidovudine with lamivudine (Figure 1).

Virologic and immunologic outcomes
Data were available for all 218 patients at the 6-month follow-up. The median time to follow-up was 182 days. Data
were available for 169 patients at the 12-month follow-up.
The median time to follow-up for this group was 364 days.
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Outcomes are shown in Table 2. Of patients on STR, 77%
had an undetectable HIV viral load at 6 months compared to
61% of patients on MTR (p = 0.012). These numbers
improved at 12 months to 82% on STR arm and 66% on
MTR arm (p = 0.019), but the STR continued to show statistically significant higher rates of HIV virologic suppression
compared to the MTR arm. At 6 months, the STR group had
a significantly greater CD4 cell increase; however, CD4
count increases at 12 months were similar.
We also looked for differences in HIV virologic outcomes
among specific subpopulations (Table 3). Both men and
women in the STR group had higher rates of virologic suppression compared to their counterparts in the MTR group;
however, statistical significance was only seen for men at the
6-month time point, perhaps because of lower numbers of
women at both time points and men at the 12-month time
point.

Regimen switching
Eleven patients of the 218 studied switched regimens
between the 6-month and 12-month measurements. At the
time of switch, 8 patients had a detectable viral load and 3
had an undetectable viral load. Four patients switched from
STR to MTR, of which 3 had a detectable viral load at the

time of switch. Two patients switched from one STR formulation to another, both with an undetectable viral load at the
time of switch. Four patients switched from one MTR to
another, and 1 from MTR to STR and all of these had detectable viral loads at the time of switch.

Multivariate regression
Multivariate log binomial regression analysis to obtain RRs
was performed controlling for demographic variables, baseline viral load, and history of substance abuse or mental illness as documented at the start of the study (Model A in
Table 4). RR of virologic failure defined as any detectable
viral load at 6 months was 1.6 (95% confidence interval (CI):
1.1–2.5) for patients on MTR compared to STR. At
12 months, RR of failure (MTR compared with STR) was 2.2
(95% CI: 1.2–4.0). Substance abuse, mental illness, gender,
and age at enrollment were not found to be significant
variables.
Regression analysis showed a similar effect when assessing only Black and Hispanic patients, who accounted for
most of the study population, controlling for above variables
(Model B in Table 4). RR of failure on MTR compared to
STR was 1.8 (95% CI: 1.1–2.9) at 6 months and 2.2 (95% CI:
1.2–4.3) at 12 months.

Discussion

Figure 1. Multiple-tablet regimen components.

Atazanavir, darunavir, fosamprenavir, and lopinavir regimens included
ritonavir for pharmacologic boosting. All regimens included dual nucleoside reverse transcriptase inhibitor backbone.

In this retrospective analysis of 218 treatment-naïve HIV
infected persons in an urban US population, we found that
initiation and maintenance of STR were associated with a
significantly increased probability of undetectable HIV viral
load at both 6 months and 12 months after initiation of therapy. This effect remained significant even when controlling
for baseline viral load as well as age, gender, self-identified
race and ethnicity, and the presence of comorbid psychiatric
illness or substance use disorder. In fact, at 12 months after
controlling for the above variables, the RR of virologic failure was over twice as high for patients on an MTR compared
to those on an STR.
Rates of virologic suppression in the STR arm of our
study were 82% at one year. This success rate is comparable

Table 2. Outcomes at 6 and 12 months by treatment group.
6-month outcome

# undetectable VL (95% CI)
Median CD4 count, mm3 (IQR)
Median change in CD4, mm3 (IQR)

12-month outcome

Single-tablet
regimens
(n = 103)

Multiple-tablet
regimens
(n = 115)

P-valuea

Single-tablet
regimens
(n = 74)

Multiple-tablet
regimens
(n = 95)

P-valuea

79 (77%)
407 (332)
+121 (124)

70 (61%)
326 (319)
+121 (172)

0.012
0.045
0.39

61 (82%)
477 (339)
+180 (219)

63 (66%)
389 (309)
+165 (224)

0.019
0.166
0.52

VL, viral load; CI, confidence interval; IQR, interquartile range.
aUsing the Pearson chi-square test for undetectable VL and Wilcoxon rank-sum for median CD4 and change in CD4.
Bold value represents an alpha of 0.05.
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Table 3. Patients with undetectable VL at 6 and 12 months.
6-month outcome

All patients (%)
Gender
Men
Women
Race/ethnicity
Black
Hispanic
Other
Baseline CD4 (mm3)
⩽200 mm3
>200 mm3
Baseline VL (copies/mL)
⩽100,000 copies/mL
>100,000 copies/mL

12-month outcome

Single-tablet
regimens
(n = 103)

Multiple-tablet
regimens
(n = 115)

P-valuea

Single-tablet
regimens
(n = 74)

Multiple-tablet
regimens
(n = 95)

P-valuea

79/103 (77%)

70/115 (61%)

0.012

61/74 (82%)

63/95 (66%)

0.019

60/77 (78%)
19/26 (73%)

39/64 (61%)
31/51 (61%)

0.028
0.286

45/56 (80%)
16/18 (89%)

36/54 (67%)
27/41 (66%)

0.104
0.06

46/56 (82%)
21/29 (72%)
12/18 (67%)

49/80 (61%)
10/16 (63%)
11/19 (58%)

0.015
0.262
0.842

34/42 (81%)
18/21 (86%)
9/11 (82%)

44/65 (68%)
10/15 (67%)
9/15 (60%)

0.199
0.171
0.226

26/35 (74%)
53/68 (78%)

28/49 (57%)
42/66 (64%)

0.106
0.068

20/26 (77%)
41/48 (85%)

23/39 (59%)
40/56 (71%)

0.135
0.086

57/70 (81%)
22/33 (67%)

46/71 (65%)
24/44 (55%)

0.026
0.284

39/47 (83%)
22/27 (81%)

43/63 (68%)
20/32 (63%)

0.079
0.109

VL, viral load.
aUsing the Pearson chi-square test for undetectable VL and Wilcoxon rank-sum for median CD4 and change in CD4.
Bold value represents an alpha of 0.05.

Table 4. Relative risk of virologic failure, all patients.
Variable

6 months

Model A: All patients
MTR vs STR
1.7 [1.1, 2.6]
Substance abuse
1.2 [0.8, 1.8]
Mental illness
1.2 [0.7, 1.9]
Female vs male
1.2 [0.8, 0.7]
Age groups
0.8 [0.5, 1.5]
Model B: Black and Hispanic patients only
MTR vs STR
1.8 [1.1, 2.6]

6 months controlling
for baseline VL

12 months

12 months controlling
for baseline VL

1.6 [1.1, 2.5]

2.2 [1.2, 4.0]
1.1 [0.7, 1.9]
0.8 [0.5, 1.3]
1.0 [0.6, 1.7]
1.0 [0.5, 2.3]

2.2 [1.2, 4.0]

1.8 [1.1, 2.9]

2.1 [1.1, 4.0]

2.2 [1.2, 4.3]

VL, viral load; STR, single-tablet regimens; MTR, multiple-tablet regimens.

to 48-week virologic suppression rates in clinical trials of
efavirenz combined with two nucleosides, which ranged
from 78% to 94%.21–29 In contrast, the rate of virologic suppression in the MTR arm, 66% at 12 months, are lower than
that observed in clinical trials of raltegravir and ritonavirboosted darunavir, atazanavir, and lopinavir, which range
from 76% for lopinavir to 86% for raltegravir.26–34 The discrepancy between our results and clinical trial results, however, is likely related to different follow-up practices and
monitoring in clinical trial populations, as well as our patient
selection.
Meta-analyses by Nachega et al.13 and Clay et al.35 found
consistent results of improved adherence and reduced risk
of virologic failure in patients with STR. A meta-analysis by
Van Galen et al.36 also suggested improved adherence
though it did not assess the effect on virologic outcomes.

Each of these analyses cited lack of randomized clinical trials addressing the issue.
An observational study in a Veterans’ Administration
cohort conducted by Sutton et al.37 found improvements in
adherence rates resulted in a statistically significant odds ratio
of 1.21 for undetectable viral load on follow-up analysis. Our
study supports these findings in a younger population with
high rates of poor insurance status. While our study was limited in the number of women enrolled, our results are consistent with an analysis in the WIHS cohort conducted by Hanna
et al.17 which found a modest improvement in virologic outcomes in a time period associated with increased STR use.
Our results are most consistent with a prospective study by
Bangsberg et al. in a cohort of homeless and marginally
housed individuals in San Francisco that compared adherence
and viral suppression between patients receiving an FDC of
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efavirenz, TDF, and emtricitabine to those receiving MTR
including non-nucleoside reverse transcriptase inhibitor and
boosted PI containing regimens. They found that adherence
was improved in the STR group compared to either of the
MTR groups. Furthermore, the proportion of individuals with
HIV viral loads <50 at 6 months was higher in the STR group
than the MTR group (69% compared to 46%, p = 0.02).14
Conversely, Engsig et al. analyzed results of the Danish HIV
Cohort Study during a period where all patients previously on
an STR were instead switched to an MTR for cost-saving purposes. This study found no significant difference in viral suppression. Notably, this study excluded patients with anticipated
problems with adherence as chosen by their physician. While
adherence was not formally measured in the study, the exclusion of patients at high risk of poor adherence may have blunted
the potential benefit of a coformulated regimen.38
It is known that adherence to therapy can be an important
marker of clinical indicators, including hospitalization, disease progression, virologic failure, and death.2–6 In prior studies, adherence has been shown to be improved in patients
initiated on once-daily regimens and those with less pill-burden, although not necessarily STR.9–19,35,36 Our study was not
able to directly measure adherence to therapy, but we suspect
the increase in adherence associated with a lower pill burden
may have helped drive the outcomes found here, specifically
virologic suppression. In addition, our study was limited to
patients who tolerated their regimens for 6 months. Since
intolerance is a common reason for switching from efavirenz,
the primary STR used in this study, we were able to highlight
the potential adherence effect of the pill formulation used,
rather than adverse events related to the component drug.39
The need for information regarding the value of STR in
HIV therapy is partially due to the anticipated arrival of
entirely generic ARV regimens. The prospect of a generic
regimen has important implications for cost-savings. An
US-based estimate of cost savings calculated that a switch
from branded therapy to generic therapy across the country
would result in a $920 million dollar cost savings in the first
year alone, or $42,500 per patient lifetime. When the same
study considered decreased effectiveness of generic regimens, the analysis suggested cost savings persisted; however, a potential loss of life expectancy was considered as a
possible concomitant result.20 The overall threshold for costeffectiveness, however, is not likely to be interpreted equally
among payer sources. One area for concern is that certain
payers, including those that serve the most vulnerable populations, would be more inclined to accept cost-savings for a
modest sacrifice in effectiveness. This is especially relevant
to our practice population, as over two-thirds of patients seen
in the practice during this study period were either enrolled
in Medicaid, uninsured, or using hospital-based charity care.
Over the past few months, we have heard anecdotes of several patients forced by their insurance providers to switch
from a STR regimen to a payer-preferred MTR regimen,
despite viral suppression on the STR. The next few years
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may tell us if these switches will become more common and
result in inferior virologic outcomes.
There are a number of limitations to this study. As a retrospective study, unmeasured confounders may exist that
impact results: including insurance status, adherence, and
provider beliefs about patients’ likely adherence. Sample
size did not allow for between-regimen comparisons in subgroups, so this study cannot compare effectiveness among
individual regimens. Nonetheless, clinical trial data and
meta-analysis have demonstrated similar rates of viral load
suppression for raltegravir, atazanavir, and darunavir—the
main regimens in the MTR group—when compared to efavirenz.40 As a consequence of the study period, a majority of
the patients on STR were placed on efavirenz/TDF/emtricitabine, and newer STR including dolutegravir/abacavir/lamivudine were not available for this study population. Perhaps
because of the high use of efavirenz as an STR and the risk
of teratogenic effects associated with this drug, fewer women
are represented in the STR group overall. This likely no
longer represents the trend, as STR without this drawback
are readily available. Finally, information for patients with
incomplete treatment before 6 months or loss-to-follow-up
before that time was not available, and this may impact interpretation of the results.
Providers’ perception of a patient’s potential adherence
may have affected regimen choice. Emergent ARV resistance is very uncommon with current boosted PI containing
regimens, and with the integrase inhibitor dolutegravir, in
contrast to the emergent resistance described among individuals failing efavirenz-containing regimens.29,41,42
Therefore, clinicians may preferentially choose boosted-PI
or integrase inhibitor containing regimens for patients determined to be high risk for medication nonadherence. While
factors leading to treatment decision making could not be
addressed directly in this study, we attempted to mitigate this
by assessing impact of age, substance use disorder, and mental illness (risk factors for non-adherence) on virologic suppression. After controlling for these factors, the favorable
effect on virologic suppression persisted in patients receiving STR. Additional unmeasured factors such as intended
pregnancy, or drug interactions, may have impacted provider
choice and are not accounted for in this analysis.
In summary, we found that daily STR had higher rates of
undetectable viral load at 6 months and 12 months of therapy
than MTR in a population of patients largely dependent on
public assistance for ARV therapy. Generic MTR are
expected to become available within the next few years,
allowing a less costly treatment option for patients and payers. While the choice between cost and convenience remains
complex, this study helps support the continued use of STR,
especially in our most vulnerable populations.
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